Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory disease requiring long-term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerability and sustained clinical efficacy for up to 1 year for pa...

Full description

Bibliographic Details
Main Authors:	Mease, PJ, Merola, JF, Tanaka, Y, Gossec, L, McInnes, IB, Ritchlin, CT, Landewé, RBM, Asahina, A, Ink, B, Heinrichs, A, Bajracharya, R, Shende, V, Coarse, J, Coates, LC
Format:	Journal article
Language:	English
Published:	Springer 2024

Similar Items

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
by: McInnes, IB, et al.
Published: (2023)

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active reference BE OPTIMAL study
by: Ritchlin, CT, et al.
Published: (2023)

Bimekizumab in patients with active psoriatic arthritis and prior inadequate response or intolerance to tumour necrosis factor inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
by: Merola, JF, et al.
Published: (2022)

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
by: Coates, LC, et al.
Published: (2024)

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
by: Robert Landewé, et al.
Published: (2024-02-01)

Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1 year results from two phase 3 studies
by: Gossec, L, et al.
Published: (2024)

Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis
by: Laure Gossec, et al.
Published: (2024-02-01)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
by: Orbai, A-M, et al.
Published: (2019)

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
by: Pournara, E, et al.
Published: (2021)

Methotrexate in psoriasis and psoriatic arthritis
by: Coates, L, et al.
Published: (2020)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
by: Coates, L, et al.
Published: (2017)

Measuring outcomes in psoriatic arthritis
by: Ogdie, A, et al.
Published: (2020)

Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free
by: Coates, LC, et al.
Published: (2021)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
by: Coates, LC, et al.
Published: (2024)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
by: Glatt, S, et al.
Published: (2019)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
by: Mease, PJ, et al.
Published: (2019)

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled tria
by: Ritchlin, CT, et al.
Published: (2023)

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
by: Coates, L, et al.
Published: (2022)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
by: Ogdie, A, et al.
Published: (2023)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
by: Coates, LC, et al.
Published: (2022)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
by: Gladman, DD, et al.
Published: (2018)

Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis
by: Rahman, P, et al.
Published: (2023)

Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis
by: Kivitz A, et al.
Published: (2023-10-01)

Psoriatic arthritis
by: FitzGerald, O, et al.
Published: (2021)

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
by: Landewé, R, et al.
Published: (2019)

Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
by: Gossec, L, et al.
Published: (2024)

Review of bimekizumab in the treatment of psoriasis
by: Sindhuja Koppu, et al.
Published: (2022-11-01)

Considerations for the definition of remission criteria in psoriatic arthritis
by: Mease, P, et al.
Published: (2017)

Comparison of different remission and low disease definitions in patients with psoriatic arthritis and evaluation of their prognostic value
by: Coates, LC, et al.
Published: (2018)

The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: similarities and differences
by: Coates, L, et al.
Published: (2022)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
by: Coates, L, et al.
Published: (2021)

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial
by: Strand, V, et al.
Published: (2024)

The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
by: Joshua Burshtein, et al.
Published: (2024-02-01)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
by: Mease, PJ, et al.
Published: (2020)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
by: Coates, LC, et al.
Published: (2024)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
by: Mease, P, et al.
Published: (2017)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
by: Baraliakos, X, et al.
Published: (2022)

Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group
by: Leung, Y-Y, et al.
Published: (2023)

GRAPPA 2018 project report
by: Goel, N, et al.
Published: (2019)

The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study
by: Petersen, MB, et al.
Published: (2023)